Pfizer Buying Cupertino-Based NextWave Pharmaceuticals For Up To $700M

CUPERTINO (CBS/AP) — Pfizer said it will buy NextWave Pharmaceuticals Inc., a company that makes a liquid attention deficit hyperactivity disorder drug, in a deal worth as much as $700 million.

The Food and Drug Administration approved NextWave’s drug Quillivant XR in September, and the once-per-day drug is expected to be in pharmacies in January.

Pfizer made a $20 million option payment to Cupertino, Calif.-based NextWave in the second quarter to establish a merger agreement. The company will pay $255 million when the deal closes, and agreed to pay NextWave another $25 million based on sales milestones.

Pfizer expects the deal to close during the fourth quarter.

Shares of Pfizer Inc. are flat at $25.76 in premarket trading.

(Copyright 2012 by CBS San Francisco. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)

 

Comments

Leave a Reply

Fill in your details below or click an icon to log in:

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

More From CBS San Francisco

Get The New CBS SF Bay Area Local App
Got Our Weather App?

Listen Live